Pomerantz Law Firm Alerts Ultragenyx Investors About Class Action Lawsuit Deadlines

Investor Alert: Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc.

Pomerantz LLP, a leading law firm renowned for its expertise in corporate, securities, and antitrust class litigation, has announced that a class action lawsuit has been initiated against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). This lawsuit is significant for those investors who have suffered losses related to their investments in Ultragenyx, as it addresses potential securities fraud and unlawful business practices by the company.

Overview of the Lawsuit

The suit asserts that Ultragenyx and certain officers and directors may have violated securities laws, resulting in financial harm to its shareholders. Investors affected by these allegations are encouraged to contact Pomerantz for guidance on joining the class action—particularly those who purchased or acquired Ultragenyx securities during the class period. The deadline for potential lead plaintiffs to come forward is April 6, 2026.

The complaint signifies that allegations of deceit in reporting and business operations could have serious consequences, both legally and financially, for Ultragenyx and its executives. Interested parties can access the complaint at Pomerantz Law Firm's website.

Key Incidents Impacting Stock Prices

The lawsuit stems from critical developments concerning Ultragenyx's clinical trials and their public disclosures. On July 9, 2025, the company and its partner, Mereo BioPharma Group plc, reported that the Phase 3 trials of the drug UX143 (setrusumab) were advancing towards a final analysis. Following this, Ultragenyx's stock price experienced a sharp decline, falling by over 25% to close at $31.04 per share a day later.

Furthermore, on December 29, 2025, Ultragenyx revealed that both the Phase 3 Orbit and Cosmic Studies failed to meet the primary endpoints for their clinical trials. This announcement led to an even steeper drop in stock price, plummeting by nearly 42% to $34.19 per share.

These significant downturns raised the alarm for investors, prompting the initiation of the class action lawsuit as shareholders sought accountability for the perceived misinformation and its financial fallout.

Pomerantz LLP: Advocates for Investors

Founded by Abraham L. Pomerantz, a pivotal figure in class action law, Pomerantz LLP has been at the forefront of advocating for shareholders' rights. With decades of experience and numerous successful recoveries for class members, the firm continues to uphold the legacy of fighting against corporate misconduct. Investors interested in participating in this class action are encouraged to reach out to Danielle Peyton at [email protected] or via phone at 646-581-9980 (toll-free: 888-4-POMLAW).

Conclusion

In summary, the ongoing class action lawsuit against Ultragenyx is crucial for shareholders affected by potential securities fraud. As the deadlines approach, affected investors should act promptly to seize their opportunity to participate in this class action. For continuous updates and legal developments, staying in contact with Pomerantz LLP is advised. They continue to stand as a resolute ally for all individuals seeking justice in securities-related matters.